CHGCY (Chugai Pharmaceutical Co) 10-Year Share Buyback Ratio : -0.10% (As of Mar. 2025)

View and export this data going back to 2008. Start your Free Trial

What is Chugai Pharmaceutical Co 10-Year Share Buyback Ratio?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

10-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past ten years. It is calculated as the annualized percentage change in shares outstanding from ten years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Chugai Pharmaceutical Co's current 10-Year Share Buyback Ratio was -0.10%.

CHGCY's 10-Year Share Buyback Ratio is ranked better than
84.06% of 621 companies
in the Drug Manufacturers industry
Industry Median: -2.8 vs CHGCY: -0.10

Competitive Comparison of Chugai Pharmaceutical Co's 10-Year Share Buyback Ratio

For the Drug Manufacturers - General subindustry, Chugai Pharmaceutical Co's 10-Year Share Buyback Ratio, along with its competitors' market caps and 10-Year Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Chugai Pharmaceutical Co's 10-Year Share Buyback Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Chugai Pharmaceutical Co's 10-Year Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Chugai Pharmaceutical Co's 10-Year Share Buyback Ratio falls into.

Save Embed

;

Save Embed

;

Chugai Pharmaceutical Co 10-Year Share Buyback Ratio Calculation

This is the annualized percentage change in shares outstanding from ten years ago to the current year. The annualized percentage change is calculated with least-square regression based on the eleven years of annual data on Shares Outstanding (EOP).

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Chugai Pharmaceutical Co (OTCPK:CHGCY) 10-Year Share Buyback Ratio Explanation

A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

Chugai Pharmaceutical Co 10-Year Share Buyback Ratio Related Terms

Thank you for viewing the detailed overview of Chugai Pharmaceutical Co's 10-Year Share Buyback Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Chugai Pharmaceutical Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Chugai Pharmaceutical Co Ltd (OTCPK:CHGCY) » Definitions » 10-Year Share Buyback Ratio

Comparable Companies

Traded in Other Exchanges

CHGCF:USA 4519N:Mexico 4519:Japan CUP:Germany

Address

1-1 Nihonbashi-Muromachi 2-Chome, Nihonbashi Mitsui Tower (Reception15F), Chuo-ku, Tokyo, JPN, 103-8324

Website

http://www.chugai-pharm.co.jp

Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan's oncology market for the past decade, largely due to drugs licensed from its parent's portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra for hemophilia A patients and Actemra for treating rheumatoid arthritis and covid patients.